Welcome to our dedicated page for Enovix Corporation SEC filings (Ticker: ENVXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ENVXW SEC filings page focuses on regulatory documents related to the Enovix Corporation warrants that traded under the ENVXW symbol. These filings help explain how the warrant program was structured, how it evolved over time, and how the ENVXW class was ultimately removed from listing on the Nasdaq Stock Market.
Key filings include multiple Form 8-K reports in which Enovix describes material events affecting the warrants. These 8-Ks summarize press releases announcing the distribution of the warrants as a dividend, the satisfaction of early expiration price conditions tied to the volume-weighted average price of Enovix common stock, the election of an alternate expiration date, and the mechanics by which warrants had to be exercised before they became void. The filings also reference a Notice of Guaranteed Delivery that outlined procedures for warrant holders whose financial institutions could not complete exercises before the deadline.
A central document for ENVXW is the Form 25 filed with the SEC, in which Nasdaq notified the Commission of the removal of the Enovix warrant class from listing and registration under Section 12(b) of the Exchange Act. This filing confirms that the ENVXW warrants, described simply as “Warrant” in the form, were struck from the exchange following the conclusion of the program.
Through Stock Titan, users can access these filings as they appear on EDGAR, while AI-powered tools can assist in interpreting the implications. For ENVXW, that means quickly understanding the timeline from warrant issuance to expiration, the conditions that triggered early expiration, and the formal delisting process. Users interested in Enovix more broadly can also look to related filings under ENVX for annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that discuss financial results, capital markets transactions and governance changes.
In addition, investors researching historical capital structure or derivative securities can use the ENVXW filings to see how the warrant terms were documented in the warrant agreement, how the company communicated with holders, and how proceeds from exercises were reported in subsequent disclosures. AI summaries can highlight the sections that address warrant exercise prices, expiration conditions, and the impact on Enovix’s equity.
Enovix Corp (ENVX) reporting person Arthi Chakravarthy, Chief Legal Officer, exercised publicly-traded warrants on 08/27/2025 to acquire 9,513 shares of common stock at an exercise price of $8.75 per share. The warrants were distributed on July 21, 2025 and each entitled the holder to purchase one share at $8.75. Following the transaction the reporting person beneficially owned 437,954 shares, which includes 333,800 shares issuable upon settlement of RSUs. The warrants had an original expiration that was accelerated when an early expiration price condition was met on 08/28/2025, making the warrants cease to be exercisable after 5:00 p.m. ET on 08/29/2025.
Pegah Ebrahimi, a director of Enovix Corporation (ENVX), exercised publicly traded warrants on 08/29/2025 to acquire 6,299 shares of common stock at an exercise price of $8.75 per share. The warrants were originally distributed on July 21, 2025 and were subject to an acceleration provision that caused the expiration to accelerate to August 29, 2025; the warrants ceased to be exercisable prior to 5:00 p.m. New York City time on that date.
After the reported transaction, Ebrahimi beneficially owned 72,939 shares, which includes 22,543 shares issuable upon settlement of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Enovix Corp (ENVX) Form 4 summary: The filing reports that warrants issued to Thurman J. Rodgers on July 21, 2025 were sold in multiple transactions on August 28–29, 2025. The warrants had an $8.75 exercise price and original expiration of October 1, 2026 that was accelerated to August 29, 2025 when an early expiration condition was met. The Form 4 discloses sales of warrants underlying up to 1,259,211 shares and an additional 655,255 warrant position; weighted-average sale prices for resulting shares ranged from approximately $0.59–$1.44 across separate transactions. Remaining warrants are held by a trust for which Rodgers is trustee and retains voting and dispositive power.
Kristina Truong, Chief Accounting Officer of Enovix Corp (ENVX), reported gift and sale transactions on August 28, 2025. She transferred 1,500 shares of common stock as a bona fide gift to each of her two children, with no purchase or sale involved. The filing also reports the public sale of 4,358 warrants that had been distributed to her at no cost on July 21, 2025; each warrant entitled the holder to buy one share at an $8.75 exercise price. The warrants’ original expiration was October 1, 2026, but an early-expiration condition accelerated the expiration to August 29, 2025, and the warrants ceased to be exercisable prior to 5:00 p.m. New York City time on that date. The reporting shows 171,225 shares represented by outstanding restricted stock units (RSUs) that are issuable upon settlement to the reporting person. The Form 4 was signed by an attorney-in-fact for Ms. Truong on September 2, 2025.
Nasdaq Stock Market LLC filed a Form 25 notifying the SEC that the class of securities for Enovix Corp (symbol ENVXW) is being removed from listing and/or registration under Section 12(b) of the Exchange Act. The filing identifies the issuer's principal office in Fremont, California, and confirms the Exchange's and/or issuer's reliance on the Form 25 rules cited. The document does not state an effective date, the reason for removal, or the signature/date of the Exchange representative.
Form 144 notice for Enovix Corporation (warrants): The filing notifies a proposed brokered sale of 1,914,466 warrants on Nasdaq with an aggregate market value of $2,641,963, scheduled approximately for 08/28/2025. The filing shows total warrants outstanding of 29,233,276, and that the warrants were acquired as dividends from the issuer on 09/24/2020 (519,853 warrants) and 07/13/2021 (1,394,613 warrants). No securities were reported sold by the holder in the past three months. Standard attestation language is included that the seller has no undisclosed material adverse information.
Enovix Corporation reported that a pricing condition for its publicly traded warrants (trading under ENVXW) has been met and that it has chosen Friday, August 29, 2025 as an alternate expiration date for these warrants. Trading in the warrants on Nasdaq will end at 4:00 p.m. New York City time on that date, and holders must exercise their warrants by 5:00 p.m. New York City time the same day. After that time, the warrants will no longer be exercisable, will be void, and any holders who have not exercised will lose all rights associated with those warrants.
Enovix Corporation announced that the volume-weighted average price (VWAP) of its common stock exceeded $10.50 for the required number of trading days, triggering the early expiration condition for its Nasdaq-listed ENVXW warrants under a July 21, 2025 Warrant Agreement. The company elected to set August 29, 2025 as the alternate expiration date for these warrants.
The ENVXW warrants are scheduled to stop trading on Nasdaq at 4:00 p.m. New York City time on August 29, 2025, and holders must exercise them by 5:00 p.m. that day, in each case so long as the VWAP of the common stock is at least $8.75 for each of the two trading days immediately before the expiration date. After 5:00 p.m. on August 29, 2025, any unexercised warrants will be void and their holders will have no further rights. A press release and a Notice of Guaranteed Delivery for warrant exercise are filed as exhibits.
Enovix Corp. director John Daniel McCranie received grants of restricted stock units (RSUs) totaling 40,878 shares on 08/12/2025, recorded on a Form 4 filed 08/26/2025. The filing shows two non‑derivative entries: 25,700 RSUs that will vest in 12 equal quarterly installments beginning August 12, 2025, and 15,178 RSUs with 25% vesting on November 12, 2025, February 12, 2026, May 12, 2026 and the earlier of June 12, 2026 or the company’s 2026 annual meeting (or immediately prior if the director does not stand for or is not re‑elected), subject to continued service.
The transactions are recorded at a $0 price per share, reflecting compensation grants rather than open‑market purchases, and the Form 4 was submitted by an attorney‑in‑fact for the reporting person.
Enovix Corp director reports no share ownership
Enovix Corp director J. Daniel McCranie filed an initial Form 3 stating that he beneficially owns no securities of the company. The filing, made as a single reporting person, confirms there are no non-derivative or derivative holdings to disclose.